Recombinant Human TRAIL/TNFSF10/CD253 (Arg115-Gly281)

Cat.No.: C022

Recombinant Human TRAIL
Description
Recombinant Human TNF-Related Apoptosis-Inducing Ligand is produced by our E.coli expression system and the target gene encoding Arg115-Gly281 is expressed.
Accession #:P50591
Known as:Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand; Apo-2L; TNF-Related Apoptosis-Inducing Ligand; Protein TRAIL; CD253; TNFSF10; APO2L; TRAIL
Formulation
Lyophilized from a 0.2 μm filtered solution of 20mM PB.250mMNacl,Ph7.5.
Quality Control
Purity:Greater than 95% as determined by reducing SDS-PAGE.
BioActivity:Measured in a cytotoxicity assay using L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is 2
Reconstitution
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Background
Human TNFSF10 is a type II transmembrane protein with an intracellular N-terminus and a ‘TNF homology domain’ (THD) at the extracellular C terminus. TNFSF10 can interact with several distinct receptors. Two of these receptors that belongs to TNFR superfamily, DR4 (TRAIL-R1) and DR5 (TRAIL-R2/TRICK2), are plasma membrane proteins containing intracellular death domains essential for activating apoptosis. TNFSF10 is promising for cancer therapy because it is cytotoxic and activates apoptosis in the majority of malignant cells, but not in normal cells.

Send Message